share_log

联康生物科技集团(00690.HK)：地夸磷索钠滴眼液上市申请已正式获国家药监局受理

Liankang Biotechnology Group (00690.HK): The marketing application for diquafinzol eye drops has been officially accepted by the State Drug Administration

Gelonghui Finance ·  Jan 23 04:35

Gelonghui, January 23丨Liankang Biotechnology Group (00690.HK) issued an announcement. The marketing application for diquaphosol eye drops submitted by the Group has been accepted by the China National Drug Administration (“NMPA”). The acceptance number is CYHS2400318. The acceptance marks a key step in the Group's expansion of ophthalmic drug reserves. If successfully approved in the future, it will provide patients with more diverse treatment options.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment